FN2 Earnings Intelligence
STERIS plc earnings overview
Latest STERIS plc (STE) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.
STERIS plc
STERIS delivered a strong fiscal 2026 close with approximately 9% revenue growth to roughly $6 billion, record adjusted EPS of $10.17, and $983 million in free cash flow. Gross margins were modestly pressured by tariffs and inflation, but EBIT margin held at 23.3%. Management struck a confident tone, announcing a dividend increase, a doubled $1 billion share-buyback authorization, and a new $60 million sterility-assurance plant in Ohio. FY27 guidance targets 7-8% revenue growth, ~50 bps of EBIT margin expansion, and EPS of $11.10-$11.30, with tariffs expected to be neutral or slightly positive. The market reacted positively with a 4.6% abnormal move on 2.6x baseline volume.
STERIS plc
STERIS's growth case remains supported by broad volume growth, strong AST capital equipment demand and onshoring-related opportunities. The near-term counterweight is that tariffs, inflation and pricing pressure are compressing margins, while management maintained rather than raised FY2026 guidance.
STERIS plc
The quarter supports a constructive view of STERIS’s near-term growth trajectory: demand across services, consumables, and capital equipment exceeded expectations, margins improved, and management raised its full-year outlook. The thesis still depends on sustaining service growth, converting backlog, and offsetting tariff and inflation pressure.
STERIS plc
The quarter supports a constructive operating picture: STERIS combined 9% reported revenue growth with 8% organic growth, modest margin expansion, and a $50 million increase to its free-cash-flow outlook. The evidence is balanced by tariff, reimbursement, regulatory, and bioprocessing-demand risks.
STERIS plc
STERIS's latest analysis supports a constructive operating trajectory: recurring consumables and services demand, stronger capital equipment execution and cost actions underpin management's outlook. The evidence is not one-sided; tariffs, legal costs, cost inflation and pharma capital-equipment uncertainty remain material tests.
STERIS plc
STERIS's recurring healthcare demand, services activity and bioprocessing strength support the operating outlook, but shipment timing, cost inflation, litigation and tariff exposure temper the case.
STERIS plc
STERIS's recurring consumables and services demand supports the case for continued growth, but the quarter does not remove concerns about margins, AST execution, capital equipment, and litigation.
Get the STE recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.